Company news

Share this article:
A US appeals court upheld a lower court ruling finding the Plavix patent valid, meaning patent protection will be maintained until November 2011. Sanofi-Aventis and Bristol-Myers Squibb are seeking damages from Canadian drug manufacturer Apotex Inc., which launched a generic version of Plavix in 2006. BMS has claimed that it lost as much as $1.75 billion in sales after Apotex's generic version of Plavix hit the market in 2006. Plavix is the world's second biggest drug and the biggest selling product for BMS and second-biggest for Sanofi, behind Lovenox. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.